Gaba A Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GABA-A receptor neurons constitute the primary mechanism for fast inhibitory neurotransmission in the mammalian brain. These ligand-gated chloride channels are expressed throughout the central nervous system and play fundamental roles in maintaining neural circuit balance, regulating neuronal excitability, and modulating cognitive functions. Dysfunction of GABA-A receptor signaling is implicated in numerous neurological and psychiatric disorders, including epilepsy, anxiety, Alzheimer's disease, and Parkinson's disease. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Ionotropic GABA receptors | [4]
| Primary Receptor | GABA-A (ionotropic, Cl- channel) | [5]
| Gene Family | GABRA, GABRB, GABRG, GABRD, etc. (19 subunits) | [6]
| Signal Transduction | Ionotropic (Cl- influx, hyperpolarization) | [7]
| Brain Regions | Throughout CNS; highest in cortex, hippocampus, cerebellum |
| Expression Pattern | Postsynaptic (majority), extrasynaptic |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
GABA-A receptors are pentameric assemblies of 19 possible subunits:
| Subunit Class | Members | Function |
|---|---|---|
| α (alpha) | α1-α6 | Benzodiazepine binding, pharmacological profiles |
| β (beta) | β1-β3 | GABA binding site |
| γ (gamma) | γ1-γ3 | Benzodiazepine site, synaptic localization |
| δ (delta) | δ | Extrasynaptic, high affinity |
| ρ (rho) | ρ1-ρ3 | GABA-C in retina |
| Subtype | Architecture | Pharmacological Profile | Brain Distribution |
|---|---|---|---|
| α1β2γ2 | α1β2γ2 | Sedative, amnesia | Widely distributed |
| α2β2γ2 | α2β2γ2 | Anxiolytic | Cortex, hippocampus |
| α3β2γ2 | α3β2γ2 | Anxiolytic, muscle relaxation | Brainstem, spinal cord |
| α5β2γ2 | α5β2γ2 | Cognitive, memory | Hippocampus |
| α4βδ | α4βδ | Extrasynaptic, tonic inhibition | Dentate gyrus, thalamus |
Extrasynaptic GABA-A receptors (α4, α5, δ subunits):
| Property | Synaptic (Phasic) | Extrasynaptic (Tonic) |
|---|---|---|
| Subunits | α1, α2, β2/3, γ2 | α4, α5, α6, δ |
| GABA source | Vesicular release | Ambient/overflow |
| Current duration | Brief (~50 ms) | Sustained |
| Deactivation | Fast | Slow |
| Location | Synaptic junction | Perisynaptic |
GABA-A receptors are primary therapeutic targets:
| Drug Class | Mechanism | Example |
|---|---|---|
| Benzodiazepines | ↑ Cl- conductance | Diazepam |
| Barbiturates | Prolong channel open time | Phenobarbital |
| GAT-1 inhibitors | Block reuptake | Tiagabine |
| GABA-T inhibitors | Block degradation | Vigabatrin |
GABAergic dysfunction contributes to AD pathophysiology:
| Drug | Target | Indication |
|---|---|---|
| Diazepam | α1,2,3,5 | Anxiety, seizures, muscle spasm |
| Lorazepam | α1,2,3,5 | Status epilepticus, anxiety |
| Alprazolam | α1,2,3,5 | Anxiety disorders |
| Phenobarbital | α1,2,3,5 | Seizures |
| Zolpidem | α1 | Insomnia |
| Tiagabine | GAT-1 | Epilepsy |
| Vigabatrin | GABA-T | Seizures |
| Compound | Target | Indication | Status |
|---|---|---|---|
| LSA-1 | α5 positive | Cognitive enhancement | Preclinical |
| Basmisanil | α5 negative | Cognitive enhancement | Discontinued |
| TPA-023 | α2,α3 positive | Anxiety | Phase II |
| Method | Application |
|---|---|
| Patch-clamp electrophysiology | Single-channel and whole-cell recording |
| Radioligand binding | Receptor density and affinity |
| Immunohistochemistry | Subunit localization |
| Knockout mice | Subtype-specific function |
| Point mutagenesis | Ligand binding sites |
| Cryo-EM | Structural biology |
The study of Gaba A Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sigel E, Steinmann ME. Structure, function, and modulation of GABA-A receptors. J Biol Chem. 2012 Nov;287(48):40224-31. 2012. ↩︎
Fritschy JM. Epilepsy, E/I balance and GABA-A receptor plasticity. Front Mol Neurosci. 2008 Oct;1:5. 2008. ↩︎
Möhler H. GABA-A receptor diversity and pharmacology. Cell Tissue Res. 2006 Dec;326(2):505-16. 2006. ↩︎
Rudolph U, Knoflach F. Beyond classical benzodiazepines: Novel therapeutic targets. Nat Rev Drug Discov. 2011 Jul;10(9):685-97. 2011. ↩︎
Rissman RA, De Blas AL, Armstrong DM. GABA-A receptors in aging and Alzheimer's disease. J Neurochem. 2007 Nov;103(4):1285-92. 2007. ↩︎
Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA-A receptors. Trends Neurosci. 2004 Aug;27(9):569-75. 2004. ↩︎
Brickley SG, Mody I. Extrasynaptic GABA-A receptors: Their function in the CNS and implications for disease. Neuron. 2012 Jan;73(1):23-34. 2012. ↩︎